• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy

    2022-09-15 03:10:50HanyongWangXinyuYangChunyanHuChenluHuangHaiWangDunwanZhuLinhuaZhang
    Chinese Chemical Letters 2022年9期

    Hanyong Wang, Xinyu Yang, Chunyan Hu, Chenlu Huang, Hai Wang, Dunwan Zhu,Linhua Zhang

    Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China

    ABSTRACT Since antigen and adjuvant are rapid clearance in vivo, insufficient delivery to induce dendritic cells (DCs)maturation and cross-presentation, as well as limited migration efficiency of DCs to secondary lymph organs, greatly hinders the development of DCs-based immunotherapy.Herein, PCL-PEG-PCL polymersomes(PCEP-PS) as antigen and adjuvants delivery nanoplatforms (IMO-PS) were well-designed, which can electrostatically adsorb OVA antigen on the surface via DOTAP lipid and effectively encapsulate OVA antigen into the inner hydrophilic cavity to achieve both initial antigen exposure as well as slow and sustained antigen release, incorporate MPLA within the lipid layer to ligate with extracellular TLR4 of DCs as well as encapsulate IMQ in the hydrophobic membrane to ligate with intracellular TLR7/8 of DCs for activating synergistic immune responses via different signaling pathways.The IMO-PS significantly improved antigen uptake, promoted DCs maturation and cytokines production.DCs treated with IMO-PS could enhance migration into draining lymphoid nodes, and eventually induced antigen-specific CD8+ and CD4+T cell responses and OVA-specific cytotoxic T lymphocyte (CTL) responses.Prophylactic vaccination of EG7-OVA tumor-bearing mice by IMO-PS+DCs significantly extended tumor-free time, effectively suppressed tumor growth, and greatly extended median survival time.The strategy may provide an effective nanoplatform for co-delivery antigen and dual-adjuvants in a spatio-temporally programmed manner for DC-based cancer immunotherapy.

    Keywords:DCs vaccine Immunotherapy Imiquimod MPLA DOTAP OVA

    As professional antigen-presenting cells, dendritic cells (DCs)play pivotal roles in both innate and adaptive immune responses[1].By processing captured antigen into peptides, DCs present them to lymphoid organs to initiate T cell or B cell immunity [2–4].Recently, DCs have been extensively used in developing DCsbased immunotherapy to treat cancer [5].DCs-based therapy includesin vitroloading of DCs with tumor or pathogen-associated antigens, activating and maturing the cells, and then reinjecting the DCs back to activate T cellsin vivo[6–8].Although DCs-based immunotherapy exhibits safety and immunogenicity, clinical responses have been largely unsatisfactory [9].There are several pitfalls restricting the effects of DCs vaccines.Among them, the main pitfall is few (~0.5%–2%) injected DCs can migrate to the lymph nodes (LNs), which hinders effective induction of T cell responses.Another drawback is inefficient stimulation of DCs to induce their maturation for the subsequent antigen-presentation to T cells, which is essential for effective DCs-based immunotherapy[1].

    Nanotechnology offers unique opportunities to tackle the clinical challenges faced by current DCs-based immunotherapy.Nanoparticles can be designed to act on DCs and regulate their functions in several distinct ways: by delivering or acting as adjuvants to optimize DCs activation, enhancing antigen internalization by targeting to DCs, facilitating exogenous antigen crosspresentationvialysosome escape, incorporating different vaccine components to help DCs to govern the activation of CD4+and CD8+T cells, or exerting intrinsic immunomodulation effect on DCs [8,10–12].Rincon-Restrepoet al.demonstrated that antigen encapsulated within the nanoparticles preferred CD4+T cell activation while antigen decorated onto the surface of NPs primarily led to CD8+T cell responses [13].Hence, nanoparticles with both surface-attached and core-encapsulated antigen might result in both CD4+and CD8+immune responses.Among various nanoparticles, polymersomes have a unique structure in which an aqueous core is enveloped by a bilayer membrane formulated by amphiphilic copolymers, entitling the vesicles with the capability of encapsulating both hydrophobic and hydrophilic molecules[14].The potential to encapsulate bioactive molecules with various physicochemical properties makes polymersomes a flexible vehicle to incorporate both antigen and adjuvants.In addition,the surface of the polymersomes can be easily further decorated with cationic lipid, which can complex with anionic peptides or proteins to generate immune responsesin vivo.1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) has been widely investigated in forming cationic liposome.DOTAP not only can adsorb anionic antigen to form vaccine carrier but also can facilitate antigen escape from the lysosome into the cytosolviaits ‘proton sponge’effect in acidic condition [15,16].Only after lysosome escape can the antigen be presentedviaMHC Ⅰpathway to activate CD8+T cells and elicit cytotoxic T-lymphocytes (CTL) response.

    Many studies demonstrated that immature DCs can be effectively activated by toll like receptor (TLR) agonists, leading to their maturation and migration to the draining LNs, where they can stimulate effector T cells [17,18].In addition, activation of TLRs on immune cells can promote the secretion of pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α, leading to enhanced innate and adaptive responses [19,20].TLR family members can be divided into endosome-associated and cell-membrane-associated receptors [21].R837 (imiquimod, IMQ) is an endosome-associated agonist for TLR7 and TLR8, which can activate DCs and induce the secretion of various pro-inflammatory factors [22].Monophosphoryl lipid A (MPLA), a detoxified form of lipopolysaccharide (LPS),can interact with membrane-associated TLR4 on DCs and activate DCs.MPLA has been repeatedly shown to enhance the release of pro-inflammatory cytokines and induce stronger T helper 1 (Th1)-biased immune responses [23,24].TLR7/8 signaling depends on myeloid differentiation primary-response gene 88 (MyD88) pathways, while TLR4 signaling is dependent on both of the My88 and TIR-domain-containing adaptor protein inducing IFN-β(TRIF) pathways [25,26].Activation of multiple signaling pathways from both the cell surface and endosome could spatially and temporally induce immune responses that are synergistic [27].TLR7/8 and TLR4 co-stimulation has been reported to significantly increase IL-12 secretion and skew DCs to improve Th1-biased responses [28,29].

    Based on the hypothesis that the immunological efficacy of lipid-polymeric hybrid NPs can be enhancedviaincorporating appropriate molecules, this study aims to compare whether the combination of both endosome-associated and cell-membraneassociated TLR agonist can achieve the highest efficacy in DCsbased immunotherapy.OVA-loaded polymersomes containing both TLR agonist MPLA and IMQ (IMO-PS), single agonist (MO-PS and IO-PS), or without agonist (O-PS) were fabricated and characterized in terms of size and size distribution, zeta potential, and OVA loading amounts.Then, immature DCs were treated with these OVAloaded polymersomes to obtain DCs-based vaccine.The cell viability, cellular uptake and effect of various OVA-loaded polymersomes on DCs maturation, cytokine secretion, and antigen crosspresentation were evaluated.In addition,in vivotracking study was carried out to evaluate the homing ability of DCs-based vaccine.Furthermore,in vivointracellular IFN-γproduction, OVA-specific CTL responses, and prophylactic vaccination effect of various DCsbased vaccines against EG7-OVA tumor model were assessed.Our study revealed that IMO-PS stimulated DCs were more efficient in cancer immunotherapy than MO-PS or IO-PS stimulated DCs,demonstrating enhanced effect of OVA-loaded polymersomes with dual agonists on DCs-based immunotherapy.

    OVA-loaded polymersomes were synthesized and characterized in our study.PCL-PEG-PCL polymersomes (PCEP-PS) co-delivery of immunostimulant molecules and OVA modal antigen were fabricated by a W/O/W method.Using this method, PCEP polymer formed an aqueous hydrophilic PEG core to encapsulate OVA inside and hydrophobic PCL membrane layer to incorporated lipophilic TLR7 agonist IMQ.TLR4 agonist MPLA was anchored into the lipid layer and outside OVA was absorbed on the outer layer of the PS surface by electronic interaction with DOTAP lipid (Fig.S1 in Supporting information).The physical parameters of the formulated PCEP-PS and the loading amounts of OVA were summarized in Table S1 (Supporting information).The average size of the PCEP-PS was detected by dynamic light scattering (DLS) and TEM.Both techniques exhibited that the hydrodynamic diameter of these PCEP-PS was ranged from 250 nm to 300 nm with a PDI of 0.31–0.41.Nanoparticles with this size are reported to effectively activate DCs and induce systemic immune responses compared to bigger particles [30].As shown in Fig.S2A (Supporting information), the TEM image showed that OVA-loaded PS had a spherical shape with some visible particles on the surface, demonstrating successfully adsorption of OVA.The zeta potential was slightly negative, indicating that the OVA was successfully absorbed on the outer layerviacationic DOTAP lipid.OVA was efficiently encapsulated in PCEP-PS with a loading amount ranged from 45 μg/mg to 57 μg/mg PS, indicating their great capability of loading antigen(Table S1).

    In vitroOVA release study was conducted in mimicking normal physiologic microenvironment (PBS, pH 7.4).Representative cumulative release curve of OVA from polymersomes was shown in Fig.S2B (Supporting information).About 20% of the antigen was released from IMO-PS within 24 h and 70% of the antigen was then continuously released for 28 days.Antigen release is one of the most important factors for particle-based vaccination.Prolonging antigen release can enable antigen persistence to immune cells, which is favorable to induce robust T cell responses [31].Meanwhile, initial antigen exposure is also important due to the quick induction of antigen-specific immune responses.The combined quick and slow antigen release from the well-designed IMOPS provided not only initial antigen exposure but also long-term antigen persistence, which was critical to enhance immune responses.

    To ensure the loading of OVA-Cy7 in PECP-PS, we usedin vivoimaging system to acquire NIR fluorescence images of prepared OVA-loaded PS.Fig.S2C (Supporting information) showed that all OVA-loaded PS groups exhibited equivalent fluorescence, while no fluorescence signals were detected in PBS group.To determine the DC labeling efficiency, DCs were incubated with OVA-Cy7 loaded PS at various concentrations (25, 50, 100 or 200 μg/mL) for 16 h and then NIR fluorescence images were obtained.As shown in Fig.S2D (Supporting information), the fluorescence signal intensity increased with the increase of concentration, and intensive NIR fluorescence from the pelleted DCs were observed at concentration higher than 50 μg/mL.

    For DC-based immune therapy, the injected DCs should be capable of keeping viable long enough to migrate to the secondary lymphoid organs and trigger an immune response.Thus, the viability of DCs after incubating with OVA-loaded PS was critical to achieve effective therapy.DC viability was assessed after being treated with various OVA-loaded PS at different OVA concentrations (25 and 50 μg/mL) for 24 and 48 h.As shown in Figs.1A and B, no cytotoxic effect was observed on BMDCs after incubating with free OVA or OVA-loaded PS, indicating the high cytocompatibility and safety of the formulated antigen carriers.

    Fig.1.Cell viability assay and in vitro PCEP-PS uptake.(A, B) Viability of DCs after treating with various OVA-loaded PCEP-PS at different OVA concentrations (A:25 μg/mL; B: 50 μg/mL) for 24 and 48 h.(C) CLSM images of antigen intracellular localization after incubating DCs with free OVA, O-PS, IO-PS, MO-PS and IMO-PS for 16 h.(D) The percentage of antigen uptake by DCs using flow cytometry analysis.???P < 0.001.

    Antigen uptake, the processing and presentation by DCs is an important step for initializing long-time memory and adaptive immunity.CLSM was used to investigate the cellar uptake and lysosome escape.As shown in Fig.1C, obvious green OVA fluorescence was observed in all the PCEP-PS groups, while very weak signal was detected in the free OVA group.This result demonstrated that PCEP-PS greatly facilitated antigen internalization by DCs.In addition, FITC-OVA was perfectly co-localized with lysosomes in free FITC-OVA group, confirming antigen degradation and processingviathe endosome/lysosome pathway.For PCEP-PS groups, although most of FITC-OVA were co-localized with lysosomes, some of them were found in the cytosol.Antigen release into cytosol is beneficial to cross-presentation for the further activation of CD4+and CD8+T cells [32,33].Antigen delivery systems mediated by NPs have been reported to be more efficient in facilitating APCs to crosspresent antigen [34–36].In our study, the lysosome escape might result from the “proton sponge” effect of cationic DOTAP, which could lead to osmotic swelling and lysosome rupture, thereby causing the cytosolic release of antigens [37].The intracellular localization of OVA confirmed that PCEP-PS enabled the endocytic delivery of exogenous antigen for presenting through both MHC I and MHC II pathways.Since TLR7 is primarily localized in the endosomal region of DCs, efficient IMQ released from the membrane of IO-PS and IMO-PS in the endosome could beneficially promote the interaction of TLR7 and IMQ agonist.The effective internalization of IMO-PS by BMDCs could result in the enhanced synergistic immune activation by both TLR4 and TLR7 signaling pathway.

    The antigen uptake capability of free OVA and various OVAloaded PS was further quantitatively analyzed by FACS.As shown in Fig.1D, free OVA group showed poor antigen uptake efficacy.Compared to O-PS, the OVA-loaded PS with TLR4 and/or TLR7 agonist (IO-PS, MO-PS and IMO-PS) showed significantly higher OVA delivery efficiency into DCs (Fig.1D).OVA-loaded PCEP-PS remarkably enhanced antigen uptake by DCs than free OVA did, contributing to that the cationic DOTAP on the outer layer of the PCEPPS could significantly facilitate antigen internalization by DCs [38].Compared with O-PS, MO-PS increased antigen uptake by DCs,which is in accordance with the previous study that MPLA incorporated in NPs enhanced uptake efficiency of antigens by APCsviathe interaction of MPLA and extracellular TLR4 agonist.Furthermore, IMO-PS group exhibited a higher cell uptake capability than IO-PS and MO-PS, implying that PS encapsulating dual TLRs could provide more efficient ligand internalization.The results above demonstrated that our polymersomes could act as an effective antigen-delivery system for preparing DCs-based vaccine.

    As one of the most important APCs, DCs not only can stimulate innate immune responses but also capture, process and present antigens to na?ve T cells to initiate adaptive immune responses.Immature DCs served as antigen-capturing cells, while mature DCs mainly acted as antigen-presenting cells [39].Thus, we analyzed DCs surface markers and secreted cytokines to assess the possible effects of O-PS, IO-PS, MO-PS and IMO-PS on DCs maturation.It was reported that antigen-loaded DCs kept in a resting state in the absence of activation and maturation stimulation, while they could efficiently facilitate adaptive immune responses when being stimulated by danger signals [40].TLR-based immune adjuvants were reported to induce enhanced expression of maturation markers such as costimulatory (CD80, CD86) molecules on DCs [41].The level of CD80 and CD86 was an important index to assess the immune response in DC-based immunotherapy [42].DOTAP liposomes were reported to improve vaccine-induced immune responses by inducing DC maturation [43].In our studies, different OVA-loaded vaccine formulations were cultured with immature DCs for 24 h, and then CD80 and CD86 expression on CD11c+cells were assessed by FACS.As shown in Fig.S3A (Supporting information), IMO-PS significantly induced higher expression of CD80 than free OVA and O-PS group.IO-PS, MO-PS and IMO-PS had higher expression of CD86 than O-PS.More importantly, the MO-PS and IMO-PS with MPLA agonist on the outer layer significantly elevated the expression of CD86 in comparison to other groups.This was probably due to that MO-PS and IMO-PS can mimic bacterial cell walls and enhance phago- and endo-cytosis by DCs as well as increase expression of costimulatory molecules and production of cytokines when MPLA ligating with TLR4 on DCs surface.Our results demonstrated that directly activating TLRs with IMQ and MPLA could synergistically promote DCs maturation.

    To assess whether immunostimulatory molecules (IMQ and/or MPLA) in PCEP-PS could affect cytokines secretion, DCs were cultured with O-PS, IO-PS, MO-PS and IMO-PS for 24 h.Cell culture supernatants were harvested and diluted to evaluate cytokines (TNF-α, IFN-γ) secretion using ELISA.As elucidated in Fig.S3C (Supporting information), the secretion of IFN-γfrom BMDCs treated with IO-PS, MO-PS, and IMO-PS was 2.0-, 2.4-, and 10.0-fold higher than that treated by O-PS group.Meanwhile, the generation of TNF-αwas also greatly augmented in PCEP-PS group with IMQ and/or MPLA agonist.As shown in Fig.S3D (Supporting information), IO-PS, MO-PS, and IMO-PS group yielded 5.5-,8.0-, and 9.0-fold higher TNF-αgeneration than O-PS group.More importantly, IMO-PS with dual agonists significantly elevated both IFN-γand TNF-αproduction compared to IO-PS and MO-PS with only single agonist.The activation of TLR7 signaling had the potential to induce DCs maturation and stimulate the secretion of proinflammatory cytokines [44,45].MPLA treated DCs were reported to be more efficient at producing Th1 cell-derived cytokine, IFN-γ[46].Our results demonstrated that the co-delivery of both TLR7 and TLR4 agonist within the polymersomes had synergistic effect on promoting the production of pro-inflammatory cytokines, which were important in DCs-based immunotherapy.

    Fig.2. In vivo tracking of various OVA-loaded PS treated DCs (A) NIR images obtained at 3, 6, 9, 24 h after injecting free OVA, O-PS and IMO-PS treated DCs(2×106) into the right footpad of C57BL/6 mice.(B) Inguinal lymph node homing of free OVA, O-PS and IMO-PS treated DCs (PBS treated group was set as control).

    Cross-presentation of endocytosed antigens could activate cytotoxic CD8+T cell and then generate antitumor immunity.To evaluate whether the formulated PCEP-PS could enhance antigen MHC I presentation, DCs were first incubated with OVA-loaded PS and then cocultured with OVA-specific LacZ B3Z CD8+T cells hybridoma.B3Z T cells could produceβ-galactosidase during the process of recognizing OVA SIINFEKL, which is presented by MHC I H-2Kb on DCs.And the producedβ-galactosidase was then quantified by CPRG, aβ-galactosidase substrate, to measure antigen crosspresentation.Fig.S3E (Supporting information) showed that compared to free OVA, OVA-loaded PS increased class I antigen presentation which may due to the increased antigen uptake in OVAloaded PS treated DCs.Furthermore, IMO-PS significantly improved the capability of cross-presentation, which may attribute to the combined effect of immune activator IMQ and MPLA.This data indicated that OVA-loaded PCEP-PS with TLR agonist, especially IMOPS with dual agonists, was superior to antigen alone in activating MHC I cross-presentation.

    In DC-based immunotherapy, migration of antigen-loaded DCs from administrated sites to draining LNsvialymphatic vessels is essential for the induction of adaptive immune responses [47].After migrating to LNs, DCs present the processed antigens in peptide form to CD4+and CD8+T cells and then initiate proper immunity against the antigens [48,49].Nevertheless, subcutaneously injected DCs were reported to migrate to the draining lymphoid tissue in a minority, while the majority were remained at the injected site [50].Thus, enhancing DCs migration into LNs is a key process to improve DC-based immunotherapeutic effect.To explore whether IMO-PS treated DCs could achieve a higherin vivomigration to the LNs, DCs (2×106cells) incubated with free OVA, OPS, and IMO-PS were injected into a left hind-leg footpad of the C57BL/6 mouse.Then, fluorescence signals were observed by thein vivoimaging system.As shown in Fig.2A, Cy7-OVA fluorescence appeared in the inguinal LNs 3 h post injection of IMO-PS treated DCs and keep strong at 24 h, whereas free OVA and OPS treated DCs showed a relatively weak fluorescence at 3 h post injection and almost no fluorescence at 24 h, implying gradual migration of IMO-PS treated DCs from the administration site to the draining lymph node through lymphatic vessels.Furthermore, DCs migration was confirmed byex vivoNIR images of dissected inguinal LNs.Fig.2B showed that IMO-PS treated DCs generated the strongest NIR signals, thus demonstrating their effective migration to the draining LNs.However, immature DCs treated with free OVA and O-PS showed a weak signal.The capability of DCs to migrate into draining LNs is essential for DCs to exert functions.Our results demonstrated that IMO-PS treated DCs remained active and achieved migration to LNs after being injected back into mice.

    To confirm antigen-specific T cell responses in immunized mice,intracellular IFN-γwas evaluated by FACS after 96 hex vivostimulation with SIINFEKL peptide.Co-delivery of antigen and adjuvant to DCs was reported to be important to induce strong CD8+T cell immune response [51].TLR activation of DCs is capable of priming antigen-specific CD4+T-helper cells, which are essential to induce antibody responses [52,53].Representative FACS plots and mean frequencies of IFN-γproducing CD4+and CD8+T cells were shown in Fig.3.As for IFN-γ+CD4+T cell in spleen, the percentage in mice immunized with IMO-PS, IO-PS and MO-PS treated DCs was 1.68% ± 0.12%, 1.22% ± 0.14%, and 1.33% ± 0.10%, respectively.On the contrary, PBS, free OVA and O-PS treated DCs immunized mice were significantly lower, with a percentage of 0.52% ± 0.12%,0.53% ± 0.14%, and 0.55% ± 0.11%, respectively.The percentage of IFN-γ+CD8+T cells detected in spleen of mice immunized with IMO-PS treated DCs was 2.44% ± 0.11%, which was significantly higher than IO-PS treated DCs (1.25% ± 0.13%) and MO-PS treated DCs (1.29% ± 0.11%).Additionally, the amount of IFN-γ+CD8+T cells was remarkably lower in mice immunized with PBS, free OVA and O-PS treated DCs, with a percentage of 0.68% ± 0.12%,0.69% ± 0.14% and 0.74% ± 0.11%, respectively.The data suggested that IMO-PS greatly improved the ability of DCs to induce antigenspecific CD8+and CD4+T cell responses.

    The OVA-loaded polymersomes could also induce OVA-specific CTL responsein vivo.CTLs, a type of T lymphocytes, can be activated by mature DCs [54] and kill infected cells or cancer cells by releasing perforin and granzymes [55].Antigen-loaded DC-based vaccines have been considered to directly induce a specific CTL response [56].Considering the increased MHC I presentation and IFN-γproduction by IMO-PS, we speculated that IMO-PS would effectively stimulate vaccine-induced CTL responses.To evaluate the OVA-specific CTL response induced by PS, mice were immunized with various PCEP-PS treated DCs.7 days after administration, splenocytes were obtained and re-stimulated with OVA peptide (SIINFEKL) in 1640 medium containing IL-2 for 72 h.Calcein-AM release assay was then used to evaluate cell viability and assess the CTL activity.The results showed that splenocytes harvested from mice immunized using IMO-PS treated DCs effectively induced CD8+T-mediated tumor cell lysis (Fig.S4A in Supporting information).The enhanced CTL responses could be contributed to the increasement of MHC I presentation and IFN-γproduction by IMO-PS.On the contrary, immunization with free OVA and OPS treated DCs failed to stimulate effective tumor specific CTL responses, in accordance with their poor effect on MHC I presentation and IFN-γsecretionin vitro.Compared with free OVA and OPS, the greatest cytotoxicity against EG7-OVA was achieved at the E:T ratio of 40:1 (Fig.S4B in Supporting information).The above results implied that IMO-PS treated DCs induced efficient antigenspecific CTL activity, demonstrating the synergistic effect of TLR4 and TLR7 signaling pathway on cellular immunity.

    Fig.3.Intracellular IFN-γ production was analyzed by FACS after splenocytes were restimulated with OVA peptide (1 μmol/L) for 96 h (n=3).Representative FACS plots of (A) IFN-γ producing CD4+ T cells and (B) IFN-γ producing CD8+ T cells.Mean frequencies of (C) IFN-γ producing CD4+ T cells and (D) IFN-γ producing CD8+ T cells.?P < 0.05, ??P < 0.01 and ???P < 0.001.

    To investigate the protective efficacy of PCEP-PS treated DCs against progressive EG7-OVA tumor, we immunized C57BL/6 mice with free OVA, O-PS, IO-PS, MO-PS, IMO-PS treated DCs (Fig.4A).PBS treated DCs were set as control group.One week after immunization, 1×106EG7-OVA cells were inoculated subcutaneously on the right back and the percentage of tumor-free mice was evaluated (Fig.4B).All mice in PBS+DCs group developed tumors within 4 days, while the mice injected with free OVA or O-PS treated DCs delayed to develop tumors within 12 days after tumor cell injection.On the contrary, 25% of mice administrated with IO-PS+DCs and MO-PS+DCs remained tumor free on day 54 post-challenge.Strikingly, the tumor free percentage was further increased to 37.5% for the mice vaccinated with IMOPS+DCs (Fig.4B).The survival rate was calculated up to 54 days after tumor inoculation.The mice vaccinated with IMO-PS showed 37.5% survival rate, while the IO-PS and MO-PS treated mice had 25% survival rate (Fig.4C).The results above suggest that IMOPS can elicit potent therapeutic anti-cancer immunity.Remarkably,the tumor-free mice in the IO-PS+DCs, MO-PS+DCs and IMOPS+DCs treated groups were re-challenged with 1×106EG7-OVA tumor cells on day 95 and they remained 100% tumor-free on day 155 (Fig.4D), confirming their capability of exhibiting long-term immunity against tumor reoccurrence.Combination of TLR4 and TLR7 ligands enhanced immune responses by synergistic effectviatriggering different pathways and thus influenced antigen dependent T-cell immune memory.These data above demonstrated that the combinational delivery of OVA, imiquimod and MPLA synergistically triggered anti-tumor immune responsesin vivo, thus achieving superior preventive effect against tumor challenge.

    Fig.4. In vivo protective efficacy of PS treated DCs.(A) Immunization schedule.(B)Percentage of tumor free mice after EG7-OVA tumor cells challenge.(C) Survival rate of EG7-OVA tumor-bearing mice.(D) Re-challenge study on tumor free mice in the IO-PS+DCs, MO-PS+DCs and IMO-PS+DCs group.Na?ve mice (n=6) were used as the control group.

    In summary, we have constructed cationic hybrid polymersomes (IMO-PS) for programmed co-delivery of OVA antigen and dual-adjuvants (IMQ and MPLA) for DC-based immunotherapy against cancer.The IMO-PS dramatically enhanced the OVA uptake in DCs and promoted DCs maturation and cytokines production.In addition, IMO-PS+DCs greatly improved DCs homing ability and OVA-specific CTL responses.Moreover, IMO-PS+DCs significantly extended tumor-free time, effectively suppressed tumor growth and greatly extended median survival time on the prophylactic EG7-OVA tumor model.Impressively, the tumor-free mice were re-challenged with EG7-OVA tumor cells on day 95 and they remained 100% tumor-free at the end of the observation time (155 days).The formulated co-delivery nanoplatform with dual agonists effectively stimulates DCs and holds great promise to be developed as DC-based vaccine for future immunotherapy treatment against cancer.

    Ethical compliance

    All animals were treated according to the regulations and guidelines of the Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College.

    Declaration of competing interest

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Acknowledgments

    This work was financially supported by National Natural Science Foundation of China (Nos.82072059 and 82172090),CAMS Initiative for Innovative Medicine (No.2021-I2M-1-058), the Fundamental Research Funds for the Central Universities (Nos.2019PT320028 and 2019-0831-03), Tianjin Municipal Natural Science Foundation (No.20JCYBJC00030).

    Supplementary materials

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2022.02.022.

    久久久精品区二区三区| 久久久久久久大尺度免费视频| 日韩一卡2卡3卡4卡2021年| 国产亚洲精品久久久久5区| 老汉色∧v一级毛片| 少妇猛男粗大的猛烈进出视频| 久久精品久久久久久噜噜老黄| 成在线人永久免费视频| 日韩 欧美 亚洲 中文字幕| 激情视频va一区二区三区| 亚洲精品国产av成人精品| 久久久久国产一级毛片高清牌| 日韩一本色道免费dvd| 欧美人与善性xxx| 狠狠精品人妻久久久久久综合| 水蜜桃什么品种好| 精品国产超薄肉色丝袜足j| 欧美精品啪啪一区二区三区 | 国产成人欧美在线观看 | 久久天堂一区二区三区四区| 悠悠久久av| 又黄又粗又硬又大视频| 国产免费视频播放在线视频| 99热网站在线观看| 婷婷色麻豆天堂久久| 97在线人人人人妻| netflix在线观看网站| 国产av国产精品国产| 国产精品 欧美亚洲| 久久九九热精品免费| 中文字幕人妻丝袜制服| 欧美激情极品国产一区二区三区| 国产一区二区三区综合在线观看| 蜜桃在线观看..| 欧美日韩亚洲高清精品| 咕卡用的链子| 人人澡人人妻人| 久久久国产一区二区| 少妇人妻 视频| 久久人妻熟女aⅴ| av有码第一页| 18禁国产床啪视频网站| 精品亚洲成国产av| 亚洲精品中文字幕在线视频| 国产精品免费视频内射| 丰满少妇做爰视频| 国产精品一区二区免费欧美 | 最黄视频免费看| 一级,二级,三级黄色视频| 丝袜美腿诱惑在线| 国产精品二区激情视频| 国产精品久久久人人做人人爽| 亚洲国产毛片av蜜桃av| 欧美亚洲日本最大视频资源| 一级a爱视频在线免费观看| 女人爽到高潮嗷嗷叫在线视频| 我的亚洲天堂| 男女高潮啪啪啪动态图| 久久久久久亚洲精品国产蜜桃av| 欧美日韩视频精品一区| 如日韩欧美国产精品一区二区三区| 日本a在线网址| 黄色视频不卡| 蜜桃在线观看..| 国产欧美日韩一区二区三 | 高清不卡的av网站| 我的亚洲天堂| 欧美日韩视频高清一区二区三区二| √禁漫天堂资源中文www| 大片电影免费在线观看免费| 一本—道久久a久久精品蜜桃钙片| 日本vs欧美在线观看视频| 免费在线观看黄色视频的| 一级片免费观看大全| 美女大奶头黄色视频| 人成视频在线观看免费观看| 香蕉丝袜av| 国产成人精品久久二区二区91| 久久久国产欧美日韩av| 91字幕亚洲| 天天躁夜夜躁狠狠躁躁| 在线观看人妻少妇| 十八禁高潮呻吟视频| 国产亚洲精品第一综合不卡| 女人高潮潮喷娇喘18禁视频| 午夜免费成人在线视频| 男人舔女人的私密视频| 亚洲欧美激情在线| 免费在线观看影片大全网站 | 一区二区三区激情视频| 九色亚洲精品在线播放| 亚洲成人免费电影在线观看 | 欧美xxⅹ黑人| 波野结衣二区三区在线| 91精品三级在线观看| 国产精品二区激情视频| 亚洲久久久国产精品| 夫妻性生交免费视频一级片| 美女脱内裤让男人舔精品视频| 成年美女黄网站色视频大全免费| 日韩熟女老妇一区二区性免费视频| 久久久久精品人妻al黑| 19禁男女啪啪无遮挡网站| av天堂在线播放| 热re99久久精品国产66热6| 少妇 在线观看| 国产在视频线精品| 少妇猛男粗大的猛烈进出视频| 午夜免费鲁丝| 久久精品国产综合久久久| 免费一级毛片在线播放高清视频 | 女性生殖器流出的白浆| 国产熟女欧美一区二区| 免费观看av网站的网址| 久久中文字幕一级| 90打野战视频偷拍视频| 夫妻性生交免费视频一级片| 亚洲成色77777| 美女高潮到喷水免费观看| 19禁男女啪啪无遮挡网站| 亚洲精品美女久久久久99蜜臀 | 在线av久久热| av片东京热男人的天堂| 视频区图区小说| 最黄视频免费看| 人人妻人人澡人人看| 亚洲欧洲国产日韩| av福利片在线| 免费观看a级毛片全部| 国产一区二区三区av在线| 欧美日韩成人在线一区二区| 嫁个100分男人电影在线观看 | a级毛片黄视频| 国产黄色视频一区二区在线观看| 亚洲欧美清纯卡通| 亚洲欧美中文字幕日韩二区| 亚洲欧美日韩另类电影网站| 国产精品久久久久久精品电影小说| 中文字幕精品免费在线观看视频| 热re99久久精品国产66热6| 国产男女内射视频| 国产视频首页在线观看| 欧美日韩视频高清一区二区三区二| av在线播放精品| 91九色精品人成在线观看| 亚洲精品日本国产第一区| 亚洲av综合色区一区| videos熟女内射| 国产欧美日韩一区二区三 | 久久精品国产综合久久久| 精品国产国语对白av| 一本大道久久a久久精品| 一级a爱视频在线免费观看| 一区二区三区激情视频| 悠悠久久av| 国产亚洲精品第一综合不卡| tube8黄色片| 欧美黄色片欧美黄色片| 在线天堂中文资源库| 国产欧美日韩精品亚洲av| 国产一区二区激情短视频 | 精品少妇黑人巨大在线播放| 19禁男女啪啪无遮挡网站| 美女脱内裤让男人舔精品视频| 天堂中文最新版在线下载| 最新的欧美精品一区二区| 99香蕉大伊视频| 欧美精品一区二区免费开放| 两性夫妻黄色片| 超色免费av| 欧美成狂野欧美在线观看| 日本wwww免费看| 国产一区二区在线观看av| 亚洲av男天堂| 国产片内射在线| 91老司机精品| 无限看片的www在线观看| 一级黄色大片毛片| 亚洲专区中文字幕在线| 美女午夜性视频免费| 国产欧美日韩一区二区三 | 精品国产国语对白av| 99国产精品一区二区三区| 日韩 亚洲 欧美在线| 亚洲图色成人| 一区福利在线观看| 黄色视频不卡| 18在线观看网站| 久久久精品国产亚洲av高清涩受| 大片电影免费在线观看免费| 欧美另类一区| 精品久久蜜臀av无| 亚洲国产精品一区三区| 欧美日韩av久久| videos熟女内射| 人人妻人人爽人人添夜夜欢视频| 90打野战视频偷拍视频| a级毛片在线看网站| 十八禁人妻一区二区| 国产97色在线日韩免费| 亚洲国产中文字幕在线视频| 精品一区二区三区av网在线观看 | 一二三四在线观看免费中文在| 国产片特级美女逼逼视频| 国产精品免费视频内射| 晚上一个人看的免费电影| 欧美国产精品va在线观看不卡| 下体分泌物呈黄色| 伊人久久大香线蕉亚洲五| 1024香蕉在线观看| 久久精品国产亚洲av涩爱| 永久免费av网站大全| 免费人妻精品一区二区三区视频| 亚洲av男天堂| 亚洲精品久久午夜乱码| 色婷婷久久久亚洲欧美| 激情视频va一区二区三区| 亚洲图色成人| 国产精品国产av在线观看| 黄色一级大片看看| 天堂中文最新版在线下载| 亚洲五月婷婷丁香| 最新在线观看一区二区三区 | 黄色怎么调成土黄色| 午夜91福利影院| 亚洲精品一卡2卡三卡4卡5卡 | 激情五月婷婷亚洲| 久久 成人 亚洲| av不卡在线播放| 亚洲欧美日韩另类电影网站| 亚洲精品在线美女| 新久久久久国产一级毛片| 午夜福利一区二区在线看| 捣出白浆h1v1| 最近最新中文字幕大全免费视频 | 丝袜脚勾引网站| 97在线人人人人妻| 蜜桃在线观看..| 免费观看人在逋| 精品国产乱码久久久久久小说| av网站在线播放免费| 99久久99久久久精品蜜桃| 国产精品国产三级国产专区5o| 亚洲 国产 在线| 午夜福利乱码中文字幕| 国产成人精品在线电影| 两性夫妻黄色片| www.熟女人妻精品国产| 亚洲国产精品成人久久小说| 纯流量卡能插随身wifi吗| 久久狼人影院| 国产成人精品在线电影| 久久99精品国语久久久| 国产精品亚洲av一区麻豆| 脱女人内裤的视频| 一区二区三区激情视频| 国产精品国产av在线观看| 欧美精品一区二区大全| 亚洲av男天堂| 黄色a级毛片大全视频| 精品福利观看| 男女午夜视频在线观看| 久久精品国产亚洲av涩爱| 一级片免费观看大全| 又大又黄又爽视频免费| 人人澡人人妻人| 精品久久久精品久久久| 中文字幕亚洲精品专区| 欧美97在线视频| 久久久国产精品麻豆| 日韩大码丰满熟妇| 日本猛色少妇xxxxx猛交久久| 天天躁日日躁夜夜躁夜夜| 欧美+亚洲+日韩+国产| avwww免费| 狠狠婷婷综合久久久久久88av| 亚洲美女黄色视频免费看| 国产激情久久老熟女| 亚洲情色 制服丝袜| 脱女人内裤的视频| 免费日韩欧美在线观看| 婷婷色av中文字幕| 伊人久久大香线蕉亚洲五| 精品人妻熟女毛片av久久网站| 欧美精品人与动牲交sv欧美| 99热国产这里只有精品6| 成人18禁高潮啪啪吃奶动态图| 欧美 亚洲 国产 日韩一| 丝瓜视频免费看黄片| 色94色欧美一区二区| 欧美人与性动交α欧美精品济南到| 夫妻午夜视频| 无限看片的www在线观看| 亚洲专区中文字幕在线| 国产精品二区激情视频| 麻豆av在线久日| 成年女人毛片免费观看观看9 | cao死你这个sao货| 老司机午夜十八禁免费视频| 亚洲av电影在线观看一区二区三区| 亚洲精品成人av观看孕妇| 人人妻人人爽人人添夜夜欢视频| 制服诱惑二区| 欧美少妇被猛烈插入视频| 婷婷色综合www| 飞空精品影院首页| 国产不卡av网站在线观看| 51午夜福利影视在线观看| 亚洲国产欧美在线一区| 美国免费a级毛片| 亚洲国产精品国产精品| 免费高清在线观看日韩| 婷婷色综合大香蕉| 黄片播放在线免费| 999久久久国产精品视频| 成年人免费黄色播放视频| 如日韩欧美国产精品一区二区三区| 久久影院123| 性色av一级| 香蕉丝袜av| 欧美黄色淫秽网站| 99九九在线精品视频| 极品少妇高潮喷水抽搐| 女人久久www免费人成看片| 中文字幕人妻熟女乱码| 看免费av毛片| 在线观看www视频免费| 国产欧美日韩精品亚洲av| 成人黄色视频免费在线看| 丰满迷人的少妇在线观看| 欧美 亚洲 国产 日韩一| 亚洲av在线观看美女高潮| 天天添夜夜摸| 久久久久网色| 久久精品久久久久久久性| 中文字幕人妻丝袜一区二区| 午夜av观看不卡| 精品少妇久久久久久888优播| 中文乱码字字幕精品一区二区三区| 新久久久久国产一级毛片| 国产欧美日韩精品亚洲av| 大话2 男鬼变身卡| 一级毛片 在线播放| 亚洲av片天天在线观看| 丁香六月天网| 成年美女黄网站色视频大全免费| 亚洲免费av在线视频| 亚洲国产最新在线播放| 波多野结衣av一区二区av| 国产成人精品久久久久久| 色综合欧美亚洲国产小说| 国产精品国产三级国产专区5o| 国产精品九九99| 亚洲欧洲日产国产| av天堂在线播放| 亚洲国产欧美一区二区综合| 亚洲欧洲精品一区二区精品久久久| 午夜激情av网站| 欧美黑人精品巨大| 国产免费福利视频在线观看| 精品久久蜜臀av无| 美女国产高潮福利片在线看| 日韩电影二区| 纵有疾风起免费观看全集完整版| 熟女少妇亚洲综合色aaa.| 中文乱码字字幕精品一区二区三区| 欧美av亚洲av综合av国产av| 亚洲av日韩在线播放| 国产男人的电影天堂91| 美女国产高潮福利片在线看| 亚洲国产精品999| 欧美成狂野欧美在线观看| 精品少妇久久久久久888优播| 蜜桃国产av成人99| 国产欧美日韩精品亚洲av| 亚洲熟女精品中文字幕| 50天的宝宝边吃奶边哭怎么回事| 国产成人欧美| 美女高潮到喷水免费观看| 在线av久久热| 成年人午夜在线观看视频| 日韩欧美一区视频在线观看| 老鸭窝网址在线观看| 激情五月婷婷亚洲| 亚洲欧美激情在线| 十八禁网站网址无遮挡| 99热国产这里只有精品6| 亚洲av片天天在线观看| 在线观看人妻少妇| 51午夜福利影视在线观看| 亚洲国产中文字幕在线视频| 亚洲精品第二区| 一本一本久久a久久精品综合妖精| 麻豆国产av国片精品| 午夜91福利影院| 日本91视频免费播放| 亚洲av日韩在线播放| 国产精品三级大全| 国产亚洲一区二区精品| videosex国产| 国产成人欧美在线观看 | 亚洲国产精品一区三区| 国产高清视频在线播放一区 | 亚洲久久久国产精品| 午夜老司机福利片| 亚洲午夜精品一区,二区,三区| 熟女av电影| 又大又黄又爽视频免费| 夜夜骑夜夜射夜夜干| 国产精品国产av在线观看| 91国产中文字幕| 国产成人a∨麻豆精品| 国产精品麻豆人妻色哟哟久久| 中国美女看黄片| 91精品伊人久久大香线蕉| 一区福利在线观看| 国产熟女午夜一区二区三区| 亚洲国产最新在线播放| 国产免费又黄又爽又色| 这个男人来自地球电影免费观看| 久久青草综合色| 涩涩av久久男人的天堂| 欧美xxⅹ黑人| 国产精品免费大片| 久久精品久久久久久久性| 国产精品.久久久| 爱豆传媒免费全集在线观看| 97精品久久久久久久久久精品| 亚洲,欧美精品.| 国产欧美日韩综合在线一区二区| 亚洲欧美清纯卡通| 黄片小视频在线播放| 桃花免费在线播放| a 毛片基地| 国产有黄有色有爽视频| 亚洲国产中文字幕在线视频| 在线观看www视频免费| 国产免费现黄频在线看| 首页视频小说图片口味搜索 | 国产av精品麻豆| svipshipincom国产片| 飞空精品影院首页| 免费观看av网站的网址| 久久久精品94久久精品| 欧美 日韩 精品 国产| 香蕉丝袜av| av天堂久久9| 乱人伦中国视频| 亚洲激情五月婷婷啪啪| 啦啦啦在线免费观看视频4| tube8黄色片| 免费高清在线观看视频在线观看| 国精品久久久久久国模美| 国产成人欧美| 叶爱在线成人免费视频播放| 午夜激情久久久久久久| 欧美成人精品欧美一级黄| 黄频高清免费视频| 91老司机精品| 波多野结衣av一区二区av| 免费人妻精品一区二区三区视频| 亚洲av片天天在线观看| h视频一区二区三区| 在线观看免费午夜福利视频| 亚洲精品日本国产第一区| 精品少妇黑人巨大在线播放| 日本一区二区免费在线视频| 久久久久久久精品精品| 精品亚洲成国产av| 只有这里有精品99| 老司机深夜福利视频在线观看 | 亚洲国产看品久久| 国产精品成人在线| 精品卡一卡二卡四卡免费| 国产又色又爽无遮挡免| 99久久精品国产亚洲精品| 啦啦啦啦在线视频资源| 男女下面插进去视频免费观看| av在线播放精品| 亚洲精品久久成人aⅴ小说| bbb黄色大片| 亚洲午夜精品一区,二区,三区| www.999成人在线观看| 爱豆传媒免费全集在线观看| 国产精品一二三区在线看| 51午夜福利影视在线观看| 亚洲色图综合在线观看| kizo精华| 亚洲国产中文字幕在线视频| 午夜免费成人在线视频| 国产精品成人在线| a 毛片基地| 性色av乱码一区二区三区2| 脱女人内裤的视频| 午夜免费男女啪啪视频观看| 欧美黄色淫秽网站| 少妇粗大呻吟视频| 婷婷色麻豆天堂久久| 99久久99久久久精品蜜桃| 亚洲成人国产一区在线观看 | 亚洲熟女毛片儿| 人体艺术视频欧美日本| 久久精品久久精品一区二区三区| 一区二区日韩欧美中文字幕| 操美女的视频在线观看| 欧美亚洲日本最大视频资源| 这个男人来自地球电影免费观看| 美国免费a级毛片| 日本黄色日本黄色录像| 国产亚洲午夜精品一区二区久久| 日韩制服丝袜自拍偷拍| 国产成人影院久久av| 久久久久网色| 人体艺术视频欧美日本| 久久99热这里只频精品6学生| 成人午夜精彩视频在线观看| 亚洲成国产人片在线观看| 飞空精品影院首页| 一级,二级,三级黄色视频| 中文字幕精品免费在线观看视频| 日韩熟女老妇一区二区性免费视频| 久久ye,这里只有精品| 国产淫语在线视频| 99久久精品国产亚洲精品| 国产亚洲av高清不卡| 欧美在线一区亚洲| 咕卡用的链子| 19禁男女啪啪无遮挡网站| 久久午夜综合久久蜜桃| 欧美黑人精品巨大| e午夜精品久久久久久久| 性色av一级| 一级,二级,三级黄色视频| 亚洲自偷自拍图片 自拍| 国产免费现黄频在线看| 成人影院久久| 欧美在线黄色| 两性夫妻黄色片| 少妇 在线观看| 在线看a的网站| 欧美日韩国产mv在线观看视频| 人人妻人人爽人人添夜夜欢视频| 熟女少妇亚洲综合色aaa.| 午夜免费成人在线视频| 在线观看免费午夜福利视频| 久久精品久久久久久久性| 亚洲一区二区三区欧美精品| 一边摸一边抽搐一进一出视频| 亚洲人成77777在线视频| 久久 成人 亚洲| 性高湖久久久久久久久免费观看| 免费在线观看日本一区| 国产伦理片在线播放av一区| 中文精品一卡2卡3卡4更新| 精品亚洲成国产av| 日韩伦理黄色片| 黄色 视频免费看| 中国美女看黄片| 国产精品99久久99久久久不卡| 国产男女超爽视频在线观看| 亚洲精品乱久久久久久| 久久久久久久大尺度免费视频| 日韩av不卡免费在线播放| 日日爽夜夜爽网站| kizo精华| 久久影院123| 一区福利在线观看| 精品欧美一区二区三区在线| 亚洲伊人色综图| av片东京热男人的天堂| 一个人免费看片子| 成年女人毛片免费观看观看9 | 亚洲精品av麻豆狂野| 一本一本久久a久久精品综合妖精| √禁漫天堂资源中文www| 亚洲国产看品久久| 啦啦啦在线观看免费高清www| 涩涩av久久男人的天堂| 精品久久久久久电影网| 午夜免费成人在线视频| 大码成人一级视频| 男人添女人高潮全过程视频| 亚洲欧洲精品一区二区精品久久久| 欧美黄色片欧美黄色片| 美女福利国产在线| 少妇裸体淫交视频免费看高清 | 亚洲国产精品一区三区| 尾随美女入室| 91老司机精品| 在线天堂中文资源库| 日日夜夜操网爽| 国产成人精品在线电影| av电影中文网址| 性色av乱码一区二区三区2| 亚洲欧美一区二区三区国产| 美女大奶头黄色视频| 亚洲五月色婷婷综合| 一级片免费观看大全| 一边摸一边做爽爽视频免费| 亚洲精品久久久久久婷婷小说| 水蜜桃什么品种好| 国产成人影院久久av| 久久av网站| 校园人妻丝袜中文字幕| 国产欧美日韩精品亚洲av| 啦啦啦视频在线资源免费观看| 免费高清在线观看日韩| 欧美乱码精品一区二区三区| 免费女性裸体啪啪无遮挡网站| 欧美精品啪啪一区二区三区 | 亚洲少妇的诱惑av| 一级毛片 在线播放| 欧美97在线视频| 国产亚洲午夜精品一区二区久久| 1024香蕉在线观看|